Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics announced upcoming presentations of data from its BTK degrader programs, NX-5948 and NX-2127, at the 66th ASH Annual Meeting in December 2024. The presentations include two oral sessions and one poster presentation. The first oral presentation will discuss efficacy and safety results from an ongoing Phase 1a/b study of NX-5948 in relapsed/refractory CLL patients. The second oral presentation will focus on how NX-2127 and NX-5948 affect T cell functionality in CLL. Additionally, a poster presentation will showcase studies on BTK degradation as a therapeutic strategy for relapsed CNS lymphoma.
Nurix Therapeutics ha annunciato le prossime presentazioni dei dati dei suoi programmi di degradosi BTK, NX-5948 e NX-2127, durante il 66° Congresso Annuale ASH a dicembre 2024. Le presentazioni includeranno due sessioni orali e una presentazione poster. La prima presentazione orale tratterà i risultati di efficacia e sicurezza di uno studio in corso di fase 1a/b su NX-5948 in pazienti con CLL in recidiva/refrattari. La seconda presentazione orale si concentrerà su come NX-2127 e NX-5948 influenzano la funzionalità delle cellule T nella CLL. Inoltre, una presentazione poster mostrerà studi sulla degradazione di BTK come strategia terapeutica per il linfoma cerebrale ricaduto.
Nurix Therapeutics anunció próximas presentaciones de datos de sus programas de degradadores de BTK, NX-5948 y NX-2127, en la 66.ª Reunión Anual de ASH en diciembre de 2024. Las presentaciones incluirán dos sesiones orales y una presentación de cartel. La primera presentación oral discutirá los resultados de eficacia y seguridad de un estudio en curso de fase 1a/b de NX-5948 en pacientes con CLL en recaída/refractarios. La segunda presentación oral se centrará en cómo NX-2127 y NX-5948 afectan la funcionalidad de las células T en la CLL. Además, una presentación de cartel mostrará estudios sobre la degradación de BTK como estrategia terapéutica para el linfoma cerebral recurrente.
Nurix Therapeutics는 2024년 12월에 열리는 제66회 ASH 연례 회의에서 NX-5948 및 NX-2127의 BTK 분해 프로그램 데이터 발표를 예고했습니다. 발표는 두 개의 구두 세션과 하나의 포스터 발표로 구성됩니다. 첫 번째 구두 발표에서는 재발/불응성 CLL 환자에서 NX-5948에 대한 진행 중인 1a/b 단계 연구의 유효성 및 안전성 결과를 논의할 것입니다. 두 번째 구두 발표는 NX-2127과 NX-5948이 CLL에서 T 세포 기능에 미치는 영향을 집중적으로 다룰 것입니다. 추가로, 포스터 발표에서는 재발한 CNS 림프종에 대한 치료 전략으로서 BTK 분해에 관한 연구를 보여줄 것입니다.
Nurix Therapeutics a annoncé les prochaines présentations des données de ses programmes de dégradation de BTK, NX-5948 et NX-2127, lors de la 66e Réunion Annuelle de l'ASH en décembre 2024. Les présentations comprendront deux sessions orales et une présentation de poster. La première présentation orale discutera des résultats d'efficacité et de sécurité d'une étude en cours de phase 1a/b sur NX-5948 chez des patients atteints de CLL récidivante/réfractaire. La deuxième présentation orale se concentrera sur l'impact de NX-2127 et NX-5948 sur la fonctionnalité des cellules T dans la CLL. De plus, une présentation de poster mettra en avant des études sur la dégradation de BTK comme stratégie thérapeutique pour le lymphome cérébral récidivant.
Nurix Therapeutics kündigte bevorstehende Präsentationen von Daten seiner BTK-Degrader-Programme, NX-5948 und NX-2127, auf dem 66. ASH-Jahrestreffen im Dezember 2024 an. Die Präsentationen umfassen zwei orale Sitzungen und eine Poster-Präsentation. Die erste orale Präsentation wird die Wirksamkeits- und Sicherheitsdaten einer laufenden Phase 1a/b-Studie zu NX-5948 bei rezidivierten/untherapierbaren CLL-Patienten thematisieren. Die zweite orale Präsentation wird sich darauf konzentrieren, wie NX-2127 und NX-5948 die T-Zell-Funktionalität in der CLL beeinflussen. Darüber hinaus wird eine Poster-Präsentation Studien zur BTK-Abbau als therapeutische Strategie für rezidivierte ZNS-Lymphome vorstellen.
- Phase 1a/b clinical trial results for NX-5948 to be presented
- Multiple presentation slots secured at major industry conference (ASH)
- Advancing research in both blood cancers and CNS lymphoma applications
- None.
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that data will be presented from its two Bruton’s tyrosine kinase (BTK) degrader programs, NX-5948 and NX-2127, in two oral presentations and one poster at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA.
Oral Presentation Details:
Title: Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study
Authors: Nirav N. Shah, Zulfa Omer, Graham Collins, Francesco Forconi, Alexey Danilov, John Byrd, Dima El Sharkawi, Emma Searle, Alvaro Alencar, Shuo Ma, Sarah Injac, Talha Munir
Session Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life
Session Date and Time: Monday, December 9, 2024, 2:45 p.m. – 4:15 p.m. PT
Presentation Time: 3:00 p.m. PT
Room: Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6
Title: NX-2127 and NX-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia
Authors: Tiana Huynh, Sonia Rodriguez-Rodriguez, Carly Roleder, Sarah Whelan, May Tan, Ernestine Lee, Paul Munson, and Alexey Danilov
Session Name: 641. Chronic Lymphocytic Leukemia: Basic and Translational: Therapeutic Vulnerabilities, Signaling, and Microenvironment
Session Date and Time: Saturday, December 7, 2024, 9:30 a.m. – 11:00 a.m. PT
Presentation Time: 10:30 a.m. PT
Room: Marriott Marquis San Diego Marina, Marriott Grand Ballroom 5-6
Poster Presentation Details
Title: BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models
Authors: Jun Ma, Michael Randall, Ming Lu, Lingjing Chen, Huimin Geng, Aishwarya Kumar, Saloni Malla, Mark Noviski, Ryan Rountree, James L. Rubenstein
Session Name: 622. Lymphomas: Translational – Non-Genetic: Poster II
Session Date and Time: Sunday, December 8, 2024, 6:00 p.m. – 8:00 p.m. PT
Location: San Diego Convention Center, Halls G-H
About NX-5948: NX-5948 is an investigational, orally bioavailable degrader of BTK that is currently being evaluated in a Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies. Additional information on the Phase 1a/b clinical trial can be accessed at www.clinicaltrials.gov (NCT05131022).
About NX-2127: NX-2127 is an investigational, orally bioavailable degrader of BTK and cereblon neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). NX-2127 is currently being evaluated in a Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies. Additional information on the ongoing clinical trial can be accessed at www.clinicaltrials.gov (NCT04830137).
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the planned timing for the provision of updates and findings from preclinical studies, including Nurix’s intention to present data from its NX-5948 and NX-2127 programs at the 66th American Society of Hematology Annual Meeting and Exposition, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended August 31, 2024, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What data will Nurix Therapeutics (NRIX) present at ASH 2024?
When will Nurix Therapeutics (NRIX) present at the 2024 ASH Annual Meeting?
What clinical trials is Nurix Therapeutics (NRIX) presenting at ASH 2024?
